Prime Movers
LyGenesis CEO Michael Hufford joins Prime Movers Lab Partner Gavin Mathis to discuss Michael's extensive background in drug development and the innovative work being done at LyGenesis in regenerative medicine. The company has found a way to turn lymph nodes into bioreactors to grow functioning ectopic organs, particularly the liver. Michael shares insights into their clinical trials, the economic implications of their therapies, and the broader applications of their technology. He also addresses the regulatory landscape and personal reflections on the challenges and future of regenerative medicine. Chapters 00:00 Introduction to LightGenesis and Michael Hufford 03:53 Innovative Approaches in Regenerative Medicine 10:00 Clinical Trials and Liver Regeneration 15:11 Economic Impact of Liver Therapy 19:50 Expanding Applications Beyond the Liver 24:52 Regulatory Landscape and Challenges 29:03 Personal Insights and Future Predictions
13 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y forma parte de la comunidad de Prime Movers!